Drug Search Results
More Filters [+]

ASP-7317

Alternative Names: asp-7317, asp7317, asp 7317
Latest Update: 2024-04-23
Latest Update Note: Clinical Trial Update

Product Description

It is for slowing or reversing atrophy in dry AMD. ASP7317 is a specially created type of cells derived from human stem cells.

Mechanisms of Action: Stem Cell Therapy

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-7317

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Geographic Atrophy|Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

7317-CL-0003

P1

Recruiting

Macular Degeneration|Geographic Atrophy

2026-01-31

Recent News Events